We characterized two reference samples for NGS technologies: a human triple-negative 69 breast cancer cell line and a matched normal cell line. Leveraging several whole-genome 70 sequencing (WGS) platforms, multiple sequencing replicates, and orthogonal mutation detection 71 bioinformatics pipelines, we minimized the potential biases from sequencing technologies, 72 assays, and informatics. Thus, our "truth sets" were defined using evidence from 21 repeats of 73 WGS runs with coverages ranging from 50X to 100X (a total of 140 billion reads). These "truth 74
Introduction
In oncology, accurate somatic mutation detection is essential to diagnose cancer, pinpoint 86 targeted therapies, predict survival, and identify resistance mutations. Despite the recent 87 explosion of technological advancements, many studies have reported difficulties in obtaining 88 consistent and concordant somatic mutation calls from individual platforms or pipelines [1] [2] [3] , which  89 hampers clinical validation and advancement of these biomarkers. 90 91
As more sequencing technologies can detect clinically actionable somatic mutations for 92 oncology, the need grows stronger for benchmark samples with known "ground-truth" variants. 93 Such a publicly available sample set would allow platform and pipeline developers to quantify 94 accuracy of somatic mutation calls, study reproducibility across platforms or pipelines, perform 95 validation usig orthogonal techniques, and calibrate best practices of protocols and methods. The 96
FDA has released a guidance on the use of NGS technologies for in vitro diagnosis of suspected 97 germline diseases 4 , in which well-characterized reference materials are recommended to 98 establish NGS test performance. 99 100
In the absence of well-characterized samples with somatic mutations, normal samples 101 such as the Platinum Genome 5 , HapMap 6 cell lines, or Genome in a Bottle (GiaB) consortium 102 materials 7,8 are often used in clinical test development and validation of somatic applications. 103
Also there are some gene-specific reference samples available, such as KRAS in the WHO 1st 104
International Reference Panel 9 , or from synthetic materials 10 . Such samples do not adequately 105 address cancer-specific quality metrics such as somatic mutation variant allele frequency (VAF), 106 heterogeneity, tumor mutation burden (TMB), etc. Therefore, cancer reference samples with an 107 abundance of well-defined genetic alterations characterized across the whole genome are highly 108 desirable and urgent needed. 109 110
Previous attempt has characterized a cancer cell line (from metastatic melanoma) that 111 inquired somatic mutations (SNV/indels) in exon regions only. Germline variants and somatic 112 mutations across the rest of the genome were not defined 11 . In addition, this dataset is 113 distributed under dbGAP-controlled access, limiting its accesibility and utility. In fact, a recent 114 landscape analysis of currently available somatic variant reference samples published by the 115
Medical Devices Innovation Consortium (MDIC) did not identify any reference mutation sets that 116
can be used to evaluate the somatic mutation calling accuracy on a whole-genome basis 12 . 117 118
To fulfill this unmet need, we chose a pair of cell lines, HCC1395 (triple-negative breast 119 cancer) and HCC395BL (B lymphocytes) from the same donor, supplied by the American Type 120
Culture Collection (ATCC). These two specific cell lines were chosen because they are rich in 121 testable features (CNVs, SNVs, indels, SVs, and genome rearrangements 13 ), and may have a 122 potential to serve as a long-term, publicly available, and renewable reference samples with 123 appropriate consent from donor. Using multiple next generation sequencing (NGS) platforms, 124 sequencing centers, and various bioinformatics analysis pipelines we profiled these tumor-125 normal matching cell lines. Thus, we minimized biases that were specific to any platform, 126 sequencing center, or bioinformatic algorithm, to create a list of high-confidence mutation calls 127 across the whole genome, here called the "truth set." A subset of these calls was further 128 confirmed with orthogonal targeted sequencing and Whole Exome Sequencing (WES). We also 129 sequenced a series of titrations between HCC1395 and HCC1395BL genomic DNA (gDNA) to 130 confirm candidate somatic SNV/indels. 131 132 We defined truth sets containing somatic mutations and germline variants in a paired cell 133 lines, HCC1395/HCC1395BL, with methods that minimized potential bias from library preparation, 134 sequencing center, or bioinformatics pipeline. While the "truth set" germline variants in 135
HCC1395BL can be used for benchmarking germline variant detection, the "truth set" somatic 136 mutations in HCC1395 can be used for benchmarking cancer mutation detection with VAF as low 137
as 5%. Many of variants and mutations have clinical implications. In the coding regions, a total of 138 193 somatic mutations are documented in the COSMIC database and 8 germline variants are 139 annotated as pathogenic in the ClinVar database. Interestingly, there is a nonsense somatic 140 mutation in the BRCA2 gene and a nonsense germline variant in the BRAC1 gene. Other hotspot 141 somatic mutations are also observed in the TP53 and FGFR1 genes. Thus, we believe these paired 142 cell lines may be highly valuable for those looking for reference samples to benchmark products 143 in detection of mutations in these four genes. 144 145
Results

147
Massive data generated to characterize the reference samples 148 149
To provide reference samples for the community well into the future, a matched pair, 150
HCC1395 and HCC1395BL was selected for profiling 14 . Previous studies of this triple negative 151 breast cancer cell line have revealed the existence of many somatic structural and ploidy 152 changes 13 , which are confirmed by our cell karyotype and cytogenetic analysis (Suppl. Fig S1, S2) . 153 Several attempts have been made to identify SNVs and small indels [15] [16] [17] . Given that appropriate 154 consent from the donor has been obtained for tumor HCC1395 and normal HCC1395BL for the 155 purposes of genomic research, we sought to characterize this pair of cell lines as publicly available 156 reference samples for the NGS community. In this manuscript, we focued our efforts on germline 157
and somatic SNVs and indels. By performing numerous sequencing experiments with multiple 158 platforms at different sequencing centers, we obtained high-confidence call sets of both somatic 159 and germline SNVs and indels ( Table 1 ). Larger structural variants and copy number analysis will 160 be included in a separate manuscript that will discuss these fundings in greater detail. applied to discover somatic mutation candidates for each pair of tumor-normal BAM files ( Fig. 1 ). 171
SomaticSeq 27 was then utilized to combine the call sets and classify the candidate mutation calls 172 into "PASS", "REJECT", or "LowQual". Four confidence levels (HighConf, MedConf, LowConf, and 173
Unclassified) were determined based on the cross-aligner and cross-sequencing center 174 reproducibility of each mutation call. HighConf and MedConf calls were grouped together as the 175 "truth set" (also known as high-confidence somatic mutations). The call set in its entirety is 176 referred to as the "super set" which includes low-confidence (LowConf) and likely false positive 177 (Unclassified) calls. For low-VAF (Variant Allele Frequency) calls, a HiSeq data set with 300× 178 coverage and a NovaSeq data set with 380× coverage were employed to rescue initial LowConf 179
and Unclassified calls into the truth set. The details are described in the Methods. 180 181
A breakdown of the four confidence levels is displayed in Fig. 2a were not reproduced enough to be high-confidence calls (Fig. 2b ).
196
Independent AmpliSeq confirmation of Call Set 197 198
We randomly selected 450 SNV and 21 indel calls of different confidence levels from the 199 super set and performed PCR-based AmpliSeq with approximately 2000× depth for tumor and 200 normal cells on an Illumina MiSeq sequencer. As we treated the AmpliSeq data set as a 201 confirmatory experiment, simple rules were devised to determine whether a variant call was 202 deemed positively confirmed, not confirmed, or uninterpretable based on the presence or 203 absense of somatic mutation evidence in the AmpliSeq data. Overall, positively confirmed calls 204 had at least 100 variant-supporting reads in the tumor but had no variant read in the normal 205 sample, despite sequencing depths of 600× or more in the normal. Not confirmed calls either 206 had no more variant-supporting read than the expected from base call errors, and/or had 207 VAF≥10% in the normal cells. Uninterpretable calls did not satisfy the criteria for either positive 208 or no validation, either because they did not have enough read depth (<50) or had fewer than 209 10 variant-supporting reads. (See Methods for details). 210 211
Both HighConf and MedConf SNV calls had very high coverage in validation and thus had 212 impressive validation rates (99% and 92%) ( Table 2 ). There were only three HighConf SNV calls 213 that were not confirmed by AmpliSeq. Two of them had germline signals below the detection 214 limit of 50× in the WGS, and the third one was likely an actual somatic mutation missed by 215
AmpliSeq. There were only seven "positively confirmed" Unclassified SNV calls. Four of those 216 seven were either a part of di-nucleotide change or had deletions within 1 bp of the call. The 217 other three had low mapping quality scores (MQ), which drove the categorization of 218 "Unclassified". This result suggests that some of the "positively confirmed" Unclassified calls 219 might be false positives after all, but it also exposes the limitations of our truth set with regard 220
to complex variants and low mappability regions. LowConf and Unclassified calls (not part of the 221 truth set) also had higher fractions of uninterpretable calls, which consist of low-coverage 222 genomic positions or ambiguous variant signals. In addition, there were also 17 HighConf, 2 223
MedConf, We have also sequenced the tumor-normal pair with Whole Exome Sequencing (WES) on 244
the Ion Torrent S5 XL sequencer with the Agilent SureSelect All Exon + UTR v6 hybrid capture. 245
The sequencing depths for the HCC1395 and HCC1395BL were 34× and 47×, respectively. 246
Results from this Ion Torrent sequencing were leveraged to evaluate high-VAF SNV calls (Table 1  247 and 2). HighConf and MedConf SNV calls had high positive validation rates (99% and 89%). 248
However, because the Ion Torrent sequencing was performed at much lower depth, nearly 50% 249 of the calls were deemed uninterpretable (compared with 16% for AmpliSeq, despite having 250
AmpliSeq custom target enriched for low-confidence calls vs. WES). The trend of higher 251 uninterpretable fraction with lower confidence level calls was even more pronounced in this data 252 set because the coverage was too low to confirm or invalidate many low-VAF calls. We used 14 HiSeq WES replicates from six sequencing centers to evaluate the 267 concordance between these data sets and the WGS data sets employed to construct the truth 268 set. While the WES data sets were not sequenced from orthogonal platforms, they provide 269 insights in terms of the reproducibility of our call sets in different library preparations. The scatter 270 plot between the super set derived VAF and medium HiSeq WES-derived VAF is presented in Fig.  271 2e. Almost all truth set (HighConf and MedConf calls) variants had consistent VAFs calculated 272 from both sources. 273 274
Again, simple rules were implemented for validation with the WES data as well (Table 2) . 275
The validation rate for HighConf, MedConf, LowConf, and Unclassified SNV calls by WES were 276 100%, 98.4%, 93.1%, and 42.4%. These validation rates are higher than other methods because 277
these WES data were sequenced on the same platform and sequencing centers as those used to 278 build the truth set. Thus, the truth set variant calls are reproducible in WES, though these data 279 sets do not eliminate sequencing center or platform specific artifacts that may exist in both WGS 280
and WES data sets. The indel equivalent is the subject of Suppl. Fig. S7c . 281 282
Validation with tumor content titration series 283 284
To evaluate the effects of tumor purity, we pooled HCC1395 DNA with HCC1395BL DNA 285 at different ratios to create a range of admixtures representing tumor purity levels of 100%, 75%, 286 50%, 20%, 10%, 5%, and 0%. For each tumor DNA dilution point, we performed WGS on a HiSeq 287 4000 with 300 × total coverage by combining three repeated runs (manuscript DOI: 288 10.1101/626440). We plotted the VAF fitting score between the expected values based on the 289 super set vs. the observed values at each tumor fraction ( Fig. 2f ). For real somatic mutations, 290 their observed VAF should scale linearly with tumor fraction in the tumor-normal titration series. 291
In contrast, the observed VAF for sequencing artifacts or germline variants will not scale in this 292
fashion. Fig. 2f replicates, aligned by the three aligners, and discovered by the four callers. We estimated the 305 SNVs/indel call probability (SCP) averaged across four factors (sequencing center, sequencing 306 replicate, aligner, and caller), and examined the variance of SCP across these factors. The SNV 307 candidates considered were called at least four times (out of a maximum of 21x3x4=252 times) 308 by various combination of the four factors. The frequency histogram of the averaged SCPs 309 demonstrates a bimodal pattern (Fig. 3a) . The vast majority of SNV calls (97%) had SCPs either 310 below 0.1 (57%) or above 0.9 (40%). Only a small minority of calls (3%) lie between 0.1 and 0.9. 311
This indicates when SNVs were repeatedly sequenced and called, only a small proportion of them 312 would be recurrently called as SNVs, and those recurrent calls were in fact highly recurrent. 313 314
Each of our germline SNV or indel calls had annotated SCP. See the Methods and Eq. 2 for 315 details. Suppl. VAF in non-exonic regions (Fig. 3b) , with a large proportion of them being uninterpretable during 323 validation. Scatter plots for indels are qualitatively similar (Suppl. Fig. S13 ). 324 325 SNV Functional Relevance and TMB Benchmarks 326 327
Among the truth set somatic mutations, 186 COSMIC SNVs and 7 COSMIC indels are in 328 the coding region. One hotspot somatic mutation of particular biological significance is a TP53 329 c.128G>A (COSMIC99023, chr17:7675088 C>T, VAF>99%), which causes an amino acid change 330 p.Arg43His that leads to the inactivation of TP53 tumor suppressive function 32 . In addition, there 331
is also a stop gain mutation in BRCA2 c.4777G>T (COSMIC13843, chr13:32339132 G>A), which 332 causes a nonsense at p.Glu1593*, though it is only a heterozygous variant with VAF of 37.5%. 333
Furthermore, there is a missense mutation in FGFR1 c.473C>T (COSM1456963, chr8: 38428420 334 G>A, VAF>99%). 335 336
Of the over 3.5 million high-confidence germline variants discovered in HCC1395BL, 9,016 337 of them are in the ClinVar database. Most of them were annotated as "benign" or "like benign"; 338 however, 8 SNVs were annotated as "pathogenic" (Suppl. regions where the alignments are challenging, base call qualities are low, and/or reported 369 coverage is far from the mean or median 36 . There are parts of the human genome that cannot be 370 covered by current technologies (Fig. 4a) . To obtain the callable regions, we ran GATK CallableLoci 371 on each of the 63 HCC1395 and HCC1395BL BAM files to identify regions of low coverage (<10), 372 ultra-high coverage (8× the mean coverage of the sample), difficult to map (MQ<20), poor 373 reads (Base Quality Score BQ < 20), or with N in the reference genome. We then created 374 consensus callable regions that we deemed callable for our truth set. A limitation of our callable 375 regions and our truth set is that they were defined and relied on short-read sequencing 376 technologies (i.e., Illumina sequencers), because currently only high-accuracy short-read 377 technologies are fit for somatic variant detection due to their low VAF. Variant calls outside the 378 consensus callable regions were labeled NonCallable in the super set and truth set to warn users 379 of these potential problems (details in Methods). NonCallable regions consisted of approximately 380 8% of the genome but contained over 34% of all Unclassified calls and 23% of all LowConf calls in 381 the super set (Suppl . Table S6 ). 382 383
The consensus callable regions consist of a total of 2.73 billion bps (Fig. 4b) Through a community effort, we generated a high confidence somatic mutation call set 401 with limit of detection (LOD) at 5% VAF (Fig. 2b) . To employ as an accuracy benchmark, we 402 recommend considering the variant calls labeled with both HighConf and MedConf as true 403 positives. These true positive variants can be used to assess sensitivity, i.e., the fraction of those 404 variants detected by a pipeline. On the other hand, variant calls labeled as Unclassified plus any 405 unspecified genomic coordinates are likely false positives. LowConf calls could not be confidently 406 determined here and should be blacklisted for current accuracy evaluation. LowConf calls had 407 validation rates around 50%, and often had VAF below our 50× depth detection limit. They 408 represent opportunities for future work to ascertain their actual somatic status. 409 410
The confidence level of each variant call was determined by the "PASS" classifications 411 provided by SomaticSeq across different sequencing centers with different aligners (see 412
Methods). If a variant was not detected by any caller in a data set, it was considered "Missing" in 413 that data set, which is common for low-VAF calls due to stochastic sampling. For most calls, 414 however, they either had "PASS" classifications or "REJECT or Missing" classifications, but not 415 both. Few variant candidates had a large number of "PASS and REJECT" classifications (Suppl. Fig.  416 S6a). HighConf calls had many "PASS" classifications, very few "REJECT" classifications, and a full 417 range of VAFs. MedConf calls had fewer "PASS" calls (still high), still very few "REJECT" 418 classifications, but were mostly low-VAF, which explains the lower number of "PASS" calls. 419
LowConf calls had even fewer "PASS" calls than MedConf though they overlaped significantly, 420 and also a low number of "REJECT" classifications. LowConf calls tended to have even lower VAF 421 than MedConf, around or below our detection limit (Fig. 2b ). Only Unclassified calls suffered a 422 significant number of "REJECT" classifications, and they also displayed a full range of VAF. The 423 performance of Unclassified calls indicated that SomaticSeq labeled them "REJECT" due to poor 424 mapping, poor alignment, germline risk, or causes other than lack of variant reads. HighConf and 425
Unclassified calls are far apart in all of the metrics describedabove. 426 427
Variant re-sequencing with AmpliSeq (Suppl. Fig. S6c ) pointed to a high validation rate for 428
HighConf and MedConf calls. Suppl. Fig. S6c also contains a cluster of Unclassified and LowConf 429 calls in the middle of the XY plane, representing calls with some conflicts (i.e., large number of 430 "PASS" and "REJECT" calls). 431 432
Each time a human cell divides, somatic mutations could be introduced by replication 433 errors. Somatic mutations can occur much more frequently in cancer cells with malfunctioning 434 DNA repair systems. It is not feasible to detect extremely low-VAF somatic mutations because 435 they may appear in few tumor cells. Our "truth set" for somatic mutation was built upon WGS 436 with 50×-100X coverages, and thus it was designed to detect somatic mutations limited to 5% of 437 VAF. Variants with low-VAF (≤12%) were cross-referenced with two data sets with depths over 438 300× to ascertain their presence. While we do not expect our truth set to be 100% accurate or 439 100% comprehensive, the AmpliSeq and Ion Torrent data sets demonstrated combined 99% and 440 91% validation rates for HighConf and MedConf SNV calls, respectively. AmpliSeq also showed a 441 94% validation rate for HighConf indel calls. VAF of 5% represents the lower detection limit of the 442 first release of the somatic mutation truth set, even though there are many true mutations with 443 VAF under that threshold. We recommend that if using this truth set as a benchmark, novel 444 variant calls (i.e., variants calls not present in our super set) with VAF<5% should be blacklisted 445 from the accuracy calculations because we cannot confidently determine their status. Due to 446 losses of chr6p, chr16q, and chrX in HCC1395BL (Suppl. Fig S1, S2) Data management: W.X., C.X., S. S. 515 516
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